TY - JOUR
T1 - Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market
T2 - An Analysis by Therapeutic Area
AU - Shibata, Shoyo
AU - Uemura, Ryotaro
AU - Suzuki, Takeshi
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported in part by Keio Gakuji Academic Development Funds and MEXT–Supported Program for the Strategic Research Foundation at Private Universities.
Publisher Copyright:
© The Author(s) 2015.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Background: A new incentive program, “Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc,” was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which these premium rewards were used. We found that orphan drugs and drugs in certain therapeutic areas, including neuroscience, oncology, and immunology, were likely to receive rewards. However, that investigation was not conducted to clarify how the rewards system affects pharmaceutical sales or whether drugs that received rewards led to more profits for pharmaceutical companies. Methods: The data set for this study was a list of the 500 top-selling pharmaceuticals in Japan from 2010 to 2014, which was obtained from the IMS Japan Pharmaceutical Market database. To clarify the effect of the rewards system on different therapeutic areas, total sales and quantity sold were compared between drugs that received rewards and those that did not. Results: The rewards system positively affected drug sales in specific therapeutic areas, including those with Anatomical Therapeutic Chemical (ATC) classifications neuroscience (N) and oncology (L), as well as the quantity sold of neuroscience-related drugs. Conclusion: Our study suggests that this system has been working according to its original aim of promoting the development of innovative drugs in Japan.
AB - Background: A new incentive program, “Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc,” was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which these premium rewards were used. We found that orphan drugs and drugs in certain therapeutic areas, including neuroscience, oncology, and immunology, were likely to receive rewards. However, that investigation was not conducted to clarify how the rewards system affects pharmaceutical sales or whether drugs that received rewards led to more profits for pharmaceutical companies. Methods: The data set for this study was a list of the 500 top-selling pharmaceuticals in Japan from 2010 to 2014, which was obtained from the IMS Japan Pharmaceutical Market database. To clarify the effect of the rewards system on different therapeutic areas, total sales and quantity sold were compared between drugs that received rewards and those that did not. Results: The rewards system positively affected drug sales in specific therapeutic areas, including those with Anatomical Therapeutic Chemical (ATC) classifications neuroscience (N) and oncology (L), as well as the quantity sold of neuroscience-related drugs. Conclusion: Our study suggests that this system has been working according to its original aim of promoting the development of innovative drugs in Japan.
KW - Japanese pharmaceutical companies
KW - drug development
KW - global pharmaceutical companies
KW - marketing strategy
KW - pricing
UR - http://www.scopus.com/inward/record.url?scp=84952777268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952777268&partnerID=8YFLogxK
U2 - 10.1177/2168479015600205
DO - 10.1177/2168479015600205
M3 - Article
AN - SCOPUS:84952777268
SN - 2168-4790
VL - 50
SP - 49
EP - 55
JO - Therapeutic Innovation and Regulatory Science
JF - Therapeutic Innovation and Regulatory Science
IS - 1
ER -
